Ann: Patent Granted for CimetrA, page-10

Malta Facility
Construction of MGC Pharma's state-of-the-art production and manufacturing facility in Malta was completed on
schedule in October, and within the parameters of the €3.1 ($4.8) million cash grant from the Maltese
Government. The production facility will have the capacity to produce over 20,000 units in liquid dose form per
day, which is double that originally planned, making it an important part of MGC's manufacturing pipeline, and
to meet CimetrA™'s near term demand. The facility is currently going through the commissioning stage, whilst
also completing the approval process to obtain a GMP licence.